Advances in systemic antifungal therapy.
Clin Dermatol. 2012 Nov-Dec;30(6):657-61
Authors: Stevens DA
After a long period of relative inactivity in the introduction of new antifungals, more recently a few new drugs of already existing classes have been introduced. These represent small or large advantages and differences compared with existing available alternative therapy for deep and systemic mycoses. The 3 newest drugs include posaconazole, micafungin, and anidulafungin, whose pharmacology, toxicology, and indications are presented.
PMID: 23068153 [PubMed - in process]